Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec 15:8:12.
doi: 10.1186/1477-5751-8-12.

PALB2 variants in hereditary and unselected Finnish prostate cancer cases

Sanna Pakkanen  1 , Tiina Wahlfors, Sanna Siltanen, Mimmi Patrikainen, Mika P Matikainen, Teuvo L J Tammela, Johanna Schleutker
Affiliations

PALB2 variants in hereditary and unselected Finnish prostate cancer cases

Sanna Pakkanen et al. J Negat Results Biomed. .

Abstract

Background: PALB2 1592delT mutation is associated with increased breast cancer and suggestive prostate cancer (PRCA) risk in Finland. In this study we wanted to assess if any other PALB2 variants associate to increased PRCA risk and clinically describe patients with formerly found PALB2 1592delT mutation.

Methods: Finnish families with two or more PRCA cases (n = 178) and unselected cases (n = 285) with complete clinical data were initially screened for variants in the coding region and splice sites of PALB2. Potentially interesting variants were verified in additional set of unselected cases (n = 463).

Results: From our clinically defined sample set we identified total of six variants in PALB2. No novel variants among Finnish PRCA cases were found. Clinical characteristics of the variant carriers, including the previously described family carrying PALB2 1592delT, revealed a trend towards aggressive disease, which also applied to a few non-familial cases. Hypersensitivity to mitomycin C (MMC) of lymphoblasts from individuals from the family with 1592delT revealed haploinsufficiency among carriers with altered genotype.

Conclusions: Though any of the detected PALB2 variants do not associate to PRCA in population level in Finland it cannot be ruled out that some of these variants contribute to cancer susceptibility at individual level.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Family 310 segregating the PALB mutation. Minus-symbol signifies a person that has been screened for the PALB2 1592delT mutation, but found negative. Clinical information on this family is found in Table 2. Index person is marked with a black triangle, black square denotes persons with prostate cancer, grey circle indicates breast cancer cases and black square with white and grey corners signifies patient with prostate, stomach and skin cancers.
Figure 2
Figure 2
Mitomycin C growth inhibition in lymphoblastoid cell lines from the 310 family. Black circle and square depicts cell lines derived from affected individuals with PALB2 1592delT mutation. Black triangle signs for control sample from healthy individual.
See this image and copyright information in PMC

References

    1. Carter HB, Coffey DS. The prostate: an increasing medical problem. Prostate. 1990;16:39–48. doi: 10.1002/pros.2990160105. - DOI - PubMed
    1. Finnish Cancer Registry. Cancer incidence and mortality in Finland. Cancer Statistics. 2007. http://www.cancerregistry.fi
    1. Kvale R, Auvinen A, Adami HO, Klint A, Hernes E, Moller B, Pukkala E, Storm HH, Tryggvadottir L, Tretli S, Wahlqvist R, Weiderpass E, Bray F. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007;99:1881–1887. doi: 10.1093/jnci/djm249. - DOI - PubMed
    1. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet. 2004;13(Spec No 1):R103–21. doi: 10.1093/hmg/ddh072. - DOI - PubMed
    1. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet. 2001;27:172–180. doi: 10.1038/84808. - DOI - PubMed

Publication types

MeSH terms